Perrigo Wary Of ‘Destroying’ Value Through Premature Sale
As Covid-19 ProAir Impact Revealed In First Quarter
Perrigo has been looking to separate its Prescription US generics business for almost two years but has ruled out an immediate or rushed transaction in existing market conditions. Meanwhile, management took the time to assess the financial rewards and ramifications of Perrigo’s recently-launched generic ProAir product, with demand “substantially higher than anticipated” in the wake of COVID-19.
